BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Monday, 19 May 1997.
As the pharmaceutical industry's first software solution that simulates clinical drug trials, MGA's ACSL BioMed enables companies to improve their drug development process by reducing the number of failed trials, reducing development costs and bringing therapies to market faster. As both small and large pharmaceutical companies compete for the revenues gained by being the first-to-market with drug therapies for cancer, AIDS, and other diseases, organizations like Pharmacia & Upjohn are using ACSL BioMed to streamline their drug development process.
"ACSL BioMed enables us to take our study designs to a higher level," said Dr. Patty Ruppel, Director of Clinical and Research Biostatistics at Pharmacia & Upjohn. "It forces us to look more carefully at how we're designing and analyzing studies and helps us to improve our trials' efficiency and focus our results. Consequently, this solution will provide value at several levels of our drug development process."
For clinical trials ranging from a single patient to thousands of patients, researchers use ACSL BioMed to design, pre-test and modify study parameters before conducting live trials. ACSL BioMed is based on MGA's powerful simulation language ACSL (Advanced Continuous Simulation Language), first developed 20 years ago and is now the standard language in continuous system simulation.
"The release of ACSL BioMed 2.1 once again reflects our customer-driven approach to product development," said Michael Gauthier, president of MGA Software. "Pharmacologists who are not familiar with our software told us that they needed an easy-to-use tool that allowed them to quickly build and simulate models of their clinical trials . The BioMed Wizard gives them a framework for the step-by-step process of building a model based on their unique set of parameters."
Pricing and Availability
ACSL BioMed 2.1 is currently available for customers with PC systems for $20,000. In addition, MGA's customers have access to the Company's superior technical support services. For help with specific modelling questions, customers can call 1-800-647-ACSL, email "support@mga.com" for on-line help, or correspond with other ACSL users at "acsl@mga.com". The Company also provides ACSL workshops on a regular basis.
MGA Software, founded in 1975, developed the first commercially successful language for modelling the dynamics of continuous systems -- ACSL (Advanced Continuous Simulation Language). Based on the Society for Computer Simulation's CSSL standard, ACSL is widely regarded as the standard software environment for modelling dynamic systems in industries such as aerospace, automotive, chemical processing, power design, agricultural and pharmaceutical research. MGA provides a full spectrum of industry solutions that include simulation specification, data analysis, hardware-in-the-loop testing, visualization and animation. Today, the privately held company has over 3,500 licenses worldwide representing over 10,000 users.
ACSL BioMed is a trademark of MGA Software Inc.
CONTACT: Michael Gauthier Jeanne MacMillan MGA Software Sterling Hager, Inc. 508-369-5115 617-259-1400 ext. 340 mikeg@mga.com jeanne@sterlinghager.com 16:48 EDT
Copyright (c) 1997/BUSINESS WIRE. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854.
970519
BW970520
Copyright © 1997 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .